Arvinas Fell While It Turned A Profit

If you backed Arvinas for its precision medicines at the start of 2026, the outcome so far has been painful. Holding Arvinas from the start of the year would have meant a 35.0% loss, including dividends. Yet the latest filing shows total revenue of US$249.7 million and net income of US$169.4 million in Q2 2026, with net margin swinging from deeply negative to strongly positive. If that was the result, what did the original investment case fail to factor in about shrinking revenue assumptions, rapid margin expansion, and very high implied future P/E multiples?

The easy part of this move is behind Arvinas. Zero in on 29 high quality undervalued stocks for companies trading below our estimates.

What Arvinas Investors Thought They Were Paying For

The shares cost US$11.86 at the start of the period, and buyers in Arvinas were effectively choosing between two competing stories about its future.

The bullish view saw fair value at US$17.44, a notional price implied by assumptions, built on precision therapies eventually supporting revenue that was expected to fall 25.2% a year while profit margin climbed to 23.3%.

The bearish camp pointed to a fair value of US$7, hinging on revenue shrinking 49.7% annually and concern that reliance on a narrow pipeline and milestone payments created sharp clinical and funding risk.

What The Results Changed For Arvinas

The sharp shift in Arvinas’ reported figures is hard to ignore. Total revenue was US$22.4 million in Q2 2025 and US$249.7 million in Q2 2026. Net income moved from a loss of US$61.2 million to a profit of US$169.4 million, with net margin moving from -273.2% to 67.8%. This clearly supported the optimistic case, although on a much shorter timescale than the multi year forecasts.

The lesson is simple. When a story leans on future margin repair and rich implied P/E multiples, keep checking the actual net margin and absolute profit each reporting season, not just the top line or share price.

What Arvinas’ Share Price Drop Now Asks You To Consider

Arvinas trades at US$7.45 today, leaving anyone who bought from the start of the year down 35.0%. The selected Narrative’s Fair Value sits above the current price and leans on a different reading of recent deals and the early pipeline.

This view focuses on Arvinas using VEPPANU economics, ARV-102 progress, and AI supported PROTAC design to sustain earnings power well beyond current modeled revenue declines.

"Key Takeaways Regaining global rights and leveraging AI-driven PROTAC design could support revenue, pipeline productivity, and longer-term earnings power through licensing or strategic transactions. Pipeline developments and industry interest in targeted protein degradation may influence Arvinas’ potential for market expansion, revenue diversification, and valuation."

The price and this Narrative do not agree. → Uncover what this Narrative says Arvinas is actually worth

Where Could You Get There Earlier?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 35% below our estimate - turns shorter brownfield tieback timelines into higher margin subsea orders and services.
• Company 2 - 33% below our estimate - converts a technology-heavy project backlog into recurring data center and modular construction work.
• Company 3 - 44% below our estimate - turns complex AI, utility risk and chemical regulation projects into repeat consulting mandates.

That is three of the list. See all 25 companies with the balance sheet to back it up →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com